Welcome to our dedicated page for Moderna SEC filings (Ticker: MRNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Moderna's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Moderna's regulatory disclosures and financial reporting.
Capital World Investors, a division of Capital Research and Management Company and related investment management entities, reported beneficial ownership of 22,276,996 shares of Moderna, Inc. common stock. This represents 5.6% of the 396,786,259 shares believed to be outstanding as of the report.
Capital World Investors has sole voting power over 22,264,639 shares and sole dispositive power over 22,276,996 shares, with no shared voting or dispositive power reported. The filing reflects passive institutional ownership rather than any stated change in control intentions.
Moderna, Inc. CEO Stéphane Bancel reported exercising stock options for 751,715 shares of common stock at $19.15 per share on August 5–6, 2026, ahead of their August 10, 2026 expiration. Pursuant to a Rule 10b5-1 trading plan adopted on May 4, 2026, he sold 499,246 shares at weighted-average prices within disclosed ranges from $55.58 to $59.34 solely to cover the option exercise price, withholding taxes, and related transaction costs, and retained the remaining shares acquired in this cashless exercise-and-hold transaction.
FMR LLC filed an amended Schedule 13G reporting a significant ownership position in Moderna Inc. common stock. As of the reporting date, FMR LLC and related entities beneficially owned 51,803,891.34 shares of Moderna common stock, representing 13.1% of the outstanding class.
FMR LLC reported sole voting power over 51,603,918.85 shares and sole dispositive power over 51,803,891.34 shares, with no shared voting or dispositive power. Abigail P. Johnson reported sole dispositive power over the same 51,803,891.34 shares but no voting power. One or more other persons may receive dividends or sale proceeds from these holdings, but no such person holds more than five percent of Moderna’s outstanding common stock.
Moderna reported second-quarter 2026 revenue of $145 million, roughly flat year over year, as net product sales fell to $94 million on lower COVID demand, offset by higher stand-ready manufacturing and collaboration revenue. The quarter’s net loss was $782 million, or $(1.97) per share.
For the first six months of 2026, revenue rose 114% to $534 million, driven by higher international COVID vaccine sales, but cost of sales jumped 401% to $1,048 million, largely from $884 million of royalties tied to a $950 million settlement with Arbutus and Genevant. This contributed to a six‑month net loss of $2,125 million and $79 million of inventory write-downs.
R&D and selling, general and administrative expenses declined versus 2025 as late-stage programs wound down and costs were tightened, while the pipeline advanced: EU approval for mCOMBRIAX, a positive FDA advisory vote for flu vaccine mRNA‑1010 (PDUFA August 5, 2026), an expanded CEPI partnership of up to $50 million, and a Recordati deal with a $50 million upfront for mRNA‑3927. Liquidity remained significant with $6,910 million in cash and investments plus a $600 million term loan and undrawn delayed-draw capacity, though a $950 million settlement payment and potential additional exposure of up to $1.3 billion and ongoing litigation remain key overhangs.
Moderna reported second quarter 2026 revenue of $145 million, slightly above the prior year, with $87 million from the U.S. and $58 million from international markets. Cost of sales were $93 million, including $41 million of inventory write-downs and $23 million of unutilized manufacturing capacity costs. Research and development expenses fell 7% to $651 million and selling, general and administrative expenses declined 6% to $216 million. Net loss was $782 million, or $1.97 per share, a $43 million improvement from a year earlier. Cash, cash equivalents and investments totaled $6.9 billion as of June 30, 2026.
For 2026, Moderna targets up to 10% revenue growth versus 2025, with roughly half of revenue from the U.S. and half from international markets and about 55% of second-half revenue recognized in the third quarter. The company now expects 2026 cost of sales of approximately $1.7 billion, research and development expenses of approximately $2.9 billion, and selling, general and administrative expenses of approximately $1.0 billion. Capital expenditures are projected at $0.2 to $0.3 billion, and year-end 2026 cash and investments are projected at $4.7 to $5.2 billion, excluding any use of the remaining $0.9 billion under its credit facility.
Pipeline and regulatory updates include a unanimous VRBPAC recommendation and August 5 PDUFA date for mFLUSIVA, which could become Moderna's fifth approved product. The company reported new approvals and contracts for mRESVIA and mNEXSPIKE, progress on its mRNA-1010 flu program, an interim miss but continued enrollment for the mRNA-1403 norovirus Phase 3 trial, and advancing oncology and rare disease programs such as intismeran and mRNA-3927.
Baillie Gifford & Co filed Amendment No. 7 to a Schedule 13G/A reporting its passive ownership in Moderna, Inc. common stock. As of 06/30/2026, Baillie Gifford & Co beneficially owned 18,206,778 shares, representing 4.59% of the outstanding common stock. It reported sole voting power over 17,920,410 shares and sole dispositive power over all 18,206,778 shares, with no shared voting or dispositive power. The filer is identified as an Investment Adviser organized in Scotland, and indicates that it now has ownership of 5 percent or less of this class.
Moderna President Stephen Hoge reported an option exercise and share sale in company stock on July 15, 2026. He exercised stock options to acquire a total of 53,336 shares of common stock at an exercise price of $19.15 per share, then sold 53,336 shares in open-market transactions at $67.60 per share pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025. Following these transactions, he reports 1,483,848 shares held directly, plus indirect interests in 151,933 shares held by a trust for the benefit of his spouse and children and 4,116 shares held by Valhalla, LLC, with beneficial ownership of the trust shares disclaimed except for any pecuniary interest.
Stephen Hoge filed a notice for a proposed sale of up to 53,336 shares of Moderna common stock. The shares are tied to a stock option exercise dated 07/15/2026, with sales planned through Fidelity Brokerage Services LLC on the NASDAQ market.
In the prior three months, Hoge sold 53,336 shares on 05/15/2026 for a value of 2,581,462.40 and another 53,336 shares on 06/15/2026 for a value of 2,739,870.32.
Moderna, Inc. director Michael R. McDonnell received equity-based compensation in the form of restricted stock units and a stock option. He was granted 5,733 RSUs vesting in full on July 8, 2027, 1,618 RSUs vesting in full on the earlier of May 6, 2027 or the next annual meeting, and an option for 7,415 shares at an exercise price of $73.80 per share that becomes fully vested and exercisable on July 8, 2027. The RSUs convert into common stock on a one-for-one basis.